Human vs. Analogue Insulin: Does Newer Really Mean Better for Type 1 Diabetes?

The choice of human vs analogue insulin is especially important for people with Type 1 diabetes who live where healthcare resources are limited. Analogue insulins are often preferred because their action can be more predictable and flexible. However, human insulin is generally less expensive and may be easier for health systems to provide consistently. New randomized research now challenges clinicians to consider an important question: Does newer insulin always produce meaningfully better outcomes?

Table of Contents

• What the HumAn-1 trial found
• Why analogue insulin became preferred
• Where human insulin remains a practical option
• Balancing safety, cost, and access
• Conclusion
• Frequently Asked Questions

What the HumAn-1 Trial Found About Insulin Choice

The 2026 HumAn-1 trial provides valuable evidence because it studied a population often underrepresented in insulin research. Researchers enrolled 400 children and young adults aged 7 to 25 with Type 1 diabetes in lower-resource settings. Participants were recruited in Bangladesh and Tanzania and randomly assigned to insulin glargine or usual care with intermediate-acting human insulin, including NPH or premixed 70/30 insulin.

At six months, researchers found no evidence that glargine improved either of the study’s primary continuous glucose monitoring outcomes. Mean time in the very low glucose range was 3.6% with glargine and 3.4% with usual care. Meanwhile, mean time in the target glucose range was 40.5% with glargine and 38.1% with usual care. The adjusted differences were not statistically significant.

Serious adverse events were uncommon in both groups, although numerically fewer occurred in the glargine group. These findings do not establish that human insulin is universally equivalent to analogue insulin. Instead, they suggest that simply replacing intermediate-acting human insulin with glargine may not automatically deliver large glucose improvements in every setting.

Why Analogue Insulin Still Has Important Advantages

Insulin analogues were designed to improve upon the action profiles of traditional human insulin. Long-acting analogues such as insulin glargine and insulin degludec generally provide flatter and more predictable basal coverage. Rapid-acting analogues such as insulin lispro and insulin aspart also act faster than regular human insulin around meals.

Those differences can matter in everyday life. For example, NPH insulin has a more pronounced peak, which can increase the possibility of unexpected or nighttime hypoglycemia. Diabetes in Control’s Type 1 Diabetes Sourcebook explains the practical differences between regular human insulin, NPH, and modern insulin analogues.

Furthermore, the American Diabetes Association Standards of Care continue to prefer insulin analogues over injectable human insulin for most adults with Type 1 diabetes to reduce hypoglycemia risk. Current evidence associates analogue insulin regimens with advantages including less hypoglycemia and greater flexibility for many patients.

Therefore, the HumAn-1 results should not be interpreted as evidence that these benefits have disappeared. Rather, the findings show that the size and importance of those advantages can depend on the patient and healthcare environment.

When Human Insulin Remains a Reasonable Option

Cost can significantly influence the choice between human and analogue insulin. A treatment cannot work if a patient cannot reliably obtain it. Consequently, an affordable insulin that remains continuously available can sometimes be more useful than a theoretically better product that is frequently unavailable.

This issue is particularly important in lower-income countries and communities where patients pay for medicines out of pocket. The World Health Organization has highlighted affordability and access when considering human versus analogue insulin. WHO guidance has historically favored human insulin in resource-limited circumstances while recognizing a role for long-acting analogues when severe hypoglycemia is a recurring concern.

Human insulin can also provide effective glucose management when patients and caregivers receive appropriate education. Regular insulin requires careful meal timing because it acts more slowly than rapid-acting analogues. Similarly, NPH has a distinct peak and generally requires more attention to timing, meals, activity, and hypoglycemia prevention.

Therefore, choosing human insulin should not simply mean prescribing a cheaper vial. Clinicians need to ensure that patients understand how its action differs from analogue insulin and have the monitoring tools and support required to use it safely.

Choosing Insulin Based on the Patient, Not the Label

The HumAn-1 trial adds an important perspective to how clinicians choose between human and analogue insulin. In a resource-limited environment, treatment decisions involve more than pharmacology. Food security, glucose monitoring, transportation, refrigeration, education, medication supply, and household finances can all affect outcomes.

For a child experiencing recurrent nocturnal hypoglycemia with NPH, switching to a long-acting analogue may provide an important clinical advantage. Likewise, a person who struggles to coordinate regular insulin with meals may benefit from the flexibility of a rapid-acting analogue.

However, another patient may be doing well with human insulin and have reliable access to it at an affordable price. Switching that person to a more expensive product without a clear clinical reason may provide limited additional value.

Consistent insulin access is particularly critical in Type 1 diabetes because insulin is essential for survival. As a result, clinicians should consider efficacy, severe hypoglycemia risk, lifestyle, glucose monitoring, patient preferences, affordability, and supply reliability together. Patients considering changes to insulin therapy should discuss their individual circumstances with a qualified healthcare professional.

Conclusion

The newest insulin is not automatically the best insulin for every person or every healthcare system. The HumAn-1 trial found no significant improvement in its primary CGM outcomes when insulin glargine was compared with usual human insulin care among children and young adults in lower-resource settings.

Still, analogue insulins offer meaningful advantages for many people, particularly through more predictable action and lower hypoglycemia risk. Human insulin, meanwhile, remains an effective and potentially important option when affordability and reliable access are major concerns.

Ultimately, the best insulin regimen is one that is safe, effective, affordable, understood by the patient or caregiver, and consistently available. The new evidence reinforces the need for individualized decisions rather than assuming that newer always means better.

Frequently Asked Questions

What is the main difference between human and analogue insulin?

Human insulin includes products such as regular insulin and NPH. Analogue insulins are modified to change how quickly they start working, when they peak, or how long their effects last.

Is analogue insulin better than human insulin for Type 1 diabetes?

Analogue insulin can reduce hypoglycemia risk and provide greater dosing flexibility for many patients. However, the HumAn-1 trial found no significant difference in its primary CGM outcomes between glargine and usual human insulin care in the population studied.

Is human insulin safe for Type 1 diabetes?

Yes. Human insulin has been used successfully for decades. However, NPH and regular insulin have different action profiles from modern analogues, so appropriate dosing, meal timing, glucose monitoring, and education are important.

Why would clinicians choose human insulin instead of an analogue?

Affordability and reliable availability are major reasons. Human insulin may be a practical option when analogue insulin is financially inaccessible or its supply is unreliable.

Should a patient switch from analogue insulin to human insulin to save money?

Patients should not change insulin types or doses without clinical guidance. Switching formulations can require changes in dose, injection timing, meal planning, and glucose monitoring.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.